BANK VONTOBEL/CALL/GILEAD SCIENCES/88/0.1/21.06.24 | Real-time Bid/Ask 14:53:51 11/06/2024 BST | ||
| 0.002 CHF / 0.041 CHF | -45.00% |
|
| 6 months | -67.21% | ||
| Current year | -82.76% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
Static data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WGIB3V | |
| ISIN | CH1260769398 |
| Date issued | 05/05/2023 |
| Strike | 88 $ |
| Maturity | 21/06/2024 (10 Days) |
| Parity | 10 : 1 |
| Emission price | 0.49 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.53 CHF |
|---|---|
| Lowest since issue | 0.04 CHF |
| Spread | 0.039 CHF |
| Spread % | 95.12% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.25
USD
Average target price
82.7
USD
Spread / Average Target
+26.74%
- Stock Market
- Warrants
- WGIB3V Warrant